NxThera raised $12.2 million in a new round of financing, according to an SEC filing posted this week.
Funds in the round come through the offering of debt, warrants, convertible promissory notes and Series C preferred stock warrants, according to the filing.
Funds in the round were raised by 28 unnamed US purchasers, according to the SEC filing, and the company has not yet stated how it plans to use funds raised.
Existing backers Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Bridge Group also participated, Maple Grove, Minn.-based NxThera said.
NxThera won CE Mark approval in the European Union in August 2013 and added FDA approval 2 years later for the Rezūm device, which uses steam to reduce the size of the prostate to relieve urinary symptoms from benign prostate hyperplasia.